⚠️ Veterinarian Alert:

Recognizing a Zorbium® Overdose in Cats

This page is written for veterinary professionals. If you have administered Zorbium® (buprenorphine transdermal solution) and your patient is declining, this information may be time-critical.

If you are a cat owner, please share this page with your veterinarian.

Why Zorbium® Is Not the Same as Injectable Buprenorphine

Zorbium® contains buprenorphine — the same active molecule found in Buprenex® and Simbadol®. However, its transdermal delivery mechanism creates a pharmacokinetic profile that differs significantly from formulations you may be more familiar with. Three factors make Zorbium® uniquely difficult to manage in an adverse event:

  • It cannot be removed. Once applied, Zorbium® continues to release buprenorphine transdermally for up to four days. There is no patch to peel off. The drug reservoir is the skin itself.[1]
  • Cats lack the enzymes to clear it normally. The domestic cat is devoid of the uridine diphosphate glucuronosyltransferase enzymes UGT1A6 and UGT1A9 that are responsible for conjugation and clearance of buprenorphine. As a result, conjugated metabolites may be absent, and clearance may be slower and less predictable than in other species.[1]
  • Bioavailability is highly variable. The absolute bioavailability of Zorbium® via transdermal administration is approximately 16% (90% CI: 11.8%–21.7%), with a terminal half-life ranging from 39.1 to 85.7 hours.[1] This wide range means individual cats may absorb substantially more or less drug than anticipated.

Signs of Zorbium® Overdose: What to Watch For

Opioid toxicity from buprenorphine may present with some or all of the following:[1,2,3]

  • Slow, shallow, or labored breathing (respiratory depression)
  • Severe sedation or inability to rouse
  • Loss of coordination (ataxia)
  • Hyperthermia — elevated body temperature (documented in clinical trials; maximum recorded 103.4°F at 20 hours post-dose)[1]
  • Elevated heart rate (average increase of 15.2 beats/minute observed in trials; maximum 231 bpm)[1]
  • Dilated pupils
  • Drooling or vocalization
  • Low body temperature (hypothermia, particularly post-anesthetic recovery)[1]

Important: Sedation alone is an expected side effect of buprenorphine. The concerning presentation is severe, progressive, or unresponsive sedation — particularly when combined with respiratory changes or temperature abnormalities.

⚠️ Critical: Naloxone May Not Work

The standard opioid reversal reflex — reaching for naloxone — may be insufficient with Zorbium®.

According to the FDA-approved package insert: “Naloxone may not be effective in reversing respiratory depression produced by buprenorphine. The onset of naloxone effect may be delayed by 30 minutes or more.”[1]

Doxapram hydrochloride has been used as a respiratory stimulant in these cases.[1]

This is not a minor pharmacological footnote. A cat in respiratory distress following Zorbium® administration may not respond to naloxone in the way you would expect from other opioids — and the delay in recognizing that could cost critical time.

The Cat That Died After Routine Surgery (Dot)

We have received accounts of cats dying following procedures as routine as spays and dental cleanings — procedures where Zorbium® was administered for post-operative pain control. In some cases, veterinarians did not connect the death to the drug.

If your patient received Zorbium® and is declining — consider opioid toxicity before ruling it out.

The FDA’s adverse event database currently documents over 333 cat deaths associated with Zorbium® since its approval in January 2022. These are reported deaths only. Pharmacovigilance research consistently shows that voluntary reporting systems capture between 1% and 10% of actual adverse events.

What You Can Do

A Note on “More Potent Than Buprenorphine”

You may encounter claims that Zorbium® is more potent than other buprenorphine formulations. This is not supported by the pharmacological literature. Zorbium® contains the identical buprenorphine molecule as other formulations. Its absolute bioavailability via transdermal administration is approximately 16%[1] — lower than many other routes of administration. The concern is not potency. The concern is unpredictable absorption, inability to withdraw the drug once applied, species-specific metabolic limitations, and the reduced efficacy of naloxone reversal.

Sources

  1. [1] Zorbium® (buprenorphine transdermal solution) — FDA-Approved Package Insert. Elanco US Inc., 2022. Published via DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
  2. [2] Buprenorphine (Buprenex®, Simbadol®, Zorbium®). PetMD Veterinary Drug Library. Reviewed by Dr. Stephanie Howe, DVM. petmd.com
  3. [3] Buprenorphine Long-Acting Transdermal (Zorbium®). VCA Animal Hospitals Drug Library. vcahospitals.com

This page was prepared for informational purposes only and does not constitute veterinary or medical advice. All clinical decisions should be made by qualified veterinary professionals. Information on this page is drawn from publicly available FDA documentation and peer-reviewed veterinary sources.